A Double Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Interferon Alfa-N3 Therapy in Addition to Standard of Care in Adults Hospitalized Due to Acute Severe Influenza - Nil

Hemispherx Biopharma Inc0 个研究点目标入组 60 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 2 期
状态: Not Applicable
发起方
入组人数: 60

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1. Age greater than equal to 18 to less than 60 years of age, male or female.
•2. Able to provide informed consent, or for whom consent may be provided by Legally Acceptable Representative or guardian.
•3. Subject must have at least two of the following five clinical presentations:
•a. Oral temperature greater than 38.0 degree Celsius (greater than 100.4 degree fahrenneit )
•b. Oxygen saturation less than 92 percent without supplemental oxygen
•c.Respiration rate less than 24 per minute
•d. Heart rate greater than 100 per minute
•e. Systolic Blood pressure less than 100 mm Hg
•4. Presence of at least one respiratory symptom (cough, sore throat, or nasal congestion) of any severity (mild, moderate, or severe).
•5. Presence of at least one constitutional symptom (headache, myalgia, feverishness (a feeling that you have a fever), or fatigue) of any severity (mild, moderate, or severe).
•6. Onset of illness no more than 72 hours before hospital admission. Note-Time of onset of illness is defined as either (1) the time when the temperature was first measured as elevated (greater than 38.0 degree Celsius (greater than 100.4 degree fehrenite), OR (2) the time when the subject experienced the presence of at least one respiratory symptom AND the presence of at least one constitutional symptom.
•7. Hospitalization criteria- Either severity of illness that, in the Investigators judgment, justifies hospitalization of the subject for supportive care, OR presence of one or more of the following factors-
•a.Presence of chronic obstructive pulmonary disease (COPD) or other chronic lung disease requiring daily pharmacotherapy.
•b.Current history of congestive heart failure or angina.
•c.Presence of diabetes mellitus, clinically stable or unstable.
•d. Transcutaneous oxygen saturation less than 94 percent without supplemental oxygen for at least 5 minutes, or a medically significant decrease in oxygen saturation from an established baseline value (an investigative site at altitude greater than 2000 ft above sea level will utilize different criteria for oxygen saturation).
•e.History of chronic renal impairment not requiring dialysis.
•f.Serum creatinine greater than 2.0 mg per dL.
•8. Diagnosis of clinical influenza with a positive Rapid Antigen Test (RAT) for influenza A and/or influenza B (using a Sponsor-approved test kit, or kits). If available at a site, a sponsor approved ELISA assay for influenza virus may be utilized.
•9. Females must be using an effective contraception method or other form of birth control prior to and during the study and use will continue through 4 weeks after completion of study drug administration.
•10. Males will ensure that their female partners of childbearing potential will utilize an effective contraceptive method or other form of birth control to avoid pregnancy.

排除标准

•1. Subjects who have developed clinical manifestations of influenza after having been hospitalized for a condition other than confirmed or suspected influenza.
•2. Blood platelet count of less than 100 x 109/L.
•3. Serum bilirubin greater than 3 mg/dL at time of screening evaluation.
•4. Serum ALT or AST greater than 3 times the upper limit of normal at time of screening evaluation.
•5. Congestive heart failure of NYHA Class III or Class IV functional status (see Appendix 18.0).
•6. Requirement for vasopressor support to maintain satisfactory hemodynamic status at time of screening evaluation.
•7. Serum creatinine greater than 3.0 mg/dL at time of screening evaluation.
•8. Subjects who require peritoneal dialysis or hemofiltration.
•9. Altered neurologic status as defined by a Glasgow Coma Score of less than or equal to 11, unless medically induced (see Appendix 19.0).
•10. Females who are pregnant (positive urine or serum pregnancy test at screening evaluation) or lactating.
•11. Actively undergoing systemic chemotherapy or radiotherapy treatment for a malignancy.
•12. A history of allergy to eggs or mice.
•13. An initial peripheral absolute neutrophil count below 1500/mm3
•14. Prior hematopoietic stem cell transplantation or solid organ transplant during the previous 4 months.
•15. Presence of a pre-existing chronic infection that is undergoing or requiring medical therapy (i.e., tuberculosis).
•16. Presence of any pre-existing illness that, in the opinion of the investigator, would place the subject at an unreasonably increased risk through participation in this study.
•17. Previous treatment with Interferons (alpha, beta or gamma) of any origin (recombinant or human leukocyte-derived).
•18. Participation as a subject in any study of an experimental treatment for any condition within the 30 days prior to the time of the screening evaluation.
•19. Subjects who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol.
•20. Subjects who can not receive subcutaneous injections.
•21. Subjects with a history of HIV disease.

研究者

发起方

Hemispherx Biopharma Inc

相似试验

进行中（未招募）

不适用

A Double Blind, Randomised, placebo-contoled Trial to establish teh safety and efficacy of a probiotic in subjects with Irritable Bowel Syndrome - not availableIrritable bowel Syndrome

EUCTR2009-015728-27-IEAlimentary Health Ltd200

已完成

2 期

Double-blind Placebo-controlled Clinical Trial of Leuprorelin acetate in Patients with Spinal and Bulbar Muscular Atrophy (SBMA)Spinal and bulbar muscular atrophy (SBMA)

JPRN-UMIN000000474Department of Neurology, Nagoya University School of Medicine40

已完成

2 期

Dyslipidaemia, Oxidative Stress And Arterial Wall Function In Non-Insulin Dependent DiabetesDyslipidaemiaMetabolic and Endocrine - DiabetesMetabolic and Endocrine - Metabolic disordersType 2 Diabetes

ACTRN12611001150932Professor Gerald F Watts80

已完成

3 期

Effect of Lignocaine Infusion in Colorectal Cancer Patient Immune CellsCancer - Bowel - Back passage (rectum) or large bowel (colon)Inflammatory and Immune System - Other inflammatory or immune system disordersAnaesthesiology - Pain managementSurgery - Other surgerycolon cancer

ACTRN12618000754246Hunter New England Local Health District107

尚未招募

4 期

Clinical study to evaluate a polyherbal product in individuals with compromised alertness, energy, concentration, and behavioral integrity due to suboptimal Sleep Quality.

CTRI/2022/09/045604Amway Global Services India Pvt Ltd